Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED by Carolyn Helms | Dec 27, 2022 | Portfolio News
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology by Carolyn Helms | Dec 12, 2022 | Portfolio News
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency by Carolyn Helms | Dec 5, 2022 | Portfolio News
Longitude Capital Expands Biotechnology Practice With Matthew Young, Former Grail COO and Jazz EVP, and Cadre of New Talent by Carolyn Helms | Nov 17, 2022 | Longitude Capital News
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline by Carolyn Helms | Nov 15, 2022 | Portfolio News
